Related Experiment Video
Updated: Jun 22, 2025
07:45
Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
3.6K
ALLOPURINOL TREATMENT IMPROVES INSULIN RESISTANCE IN NON-DIABETIC PATIENTS WITH RENAL STONE
Georgian Medical News
|July 4, 2024
Summary
Lowering uric acid with allopurinol improved insulin levels and glycemic control in non-diabetic individuals with hyperuricemia. This suggests potential benefits for managing insulin resistance and type 2 diabetes.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Nephrology
Background:
- Hyperuricemia is linked to impaired fasting glucose and type 2 diabetes (T2D).
- The direct causal role of hyperuricemia in insulin resistance remains under investigation.
- This study explores the impact of reducing uric acid levels on insulin resistance.
Purpose of the Study:
- To test if lowering uric acid in hyperuricemic, non-diabetic individuals improves insulin resistance.
- To evaluate the efficacy of allopurinol in managing metabolic parameters associated with hyperuricemia.
Main Methods:
- Fifteen patients with renal stones and hyperuricemia were treated with allopurinol (300mg/day) for six months.
- Measurements included serum uric acid (SUA), fasting serum glucose (FSG), fasting insulin, and C-peptide.
- Statistical analysis assessed significant changes in metabolic markers.
Main Results:
- Allopurinol significantly reduced C-peptide and insulin levels (P<0.05).
- A non-significant reduction in fasting serum glucose was observed (p>0.05).
- The treatment demonstrated an improvement in insulin sensitivity.
Conclusions:
- Allopurinol effectively improved insulin levels and glycemic control in hyperuricemic, non-diabetic subjects.
- Findings suggest allopurinol as a potential therapeutic agent for improving glycemic control in diabetic patients.
- Further research into allopurinol derivatives may lead to novel antidiabetic drugs.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
01:11Renal Failure: Dose Adjustments
79
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
01:23Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
01:25Antihypertensive Drugs: Direct Renin Inhibitors
546
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
546
01:28Renal Drug Excretion: Tubular Secretion
172
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
172
01:17Factors Affecting Renal Clearance: Renal Impairment
74
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
74